167 related articles for article (PubMed ID: 35973305)
1. Targeting androgen receptor for prostate cancer therapy: From small molecules to PROTACs.
Avgeris I; Pliatsika D; Nikolaropoulos SS; Fousteris MA
Bioorg Chem; 2022 Nov; 128():106089. PubMed ID: 35973305
[TBL] [Abstract][Full Text] [Related]
2. An Overview of Next-Generation Androgen Receptor-Targeted Therapeutics in Development for the Treatment of Prostate Cancer.
Mohler ML; Sikdar A; Ponnusamy S; Hwang DJ; He Y; Miller DD; Narayanan R
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672769
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and characterization of PROTACs targeting the androgen receptor in prostate and lung cancer models.
Gockel LM; Pfeifer V; Baltes F; Bachmaier RD; Wagner KG; Bendas G; Gütschow M; Sosič I; Steinebach C
Arch Pharm (Weinheim); 2022 May; 355(5):e2100467. PubMed ID: 35128717
[TBL] [Abstract][Full Text] [Related]
4. Improving Strategies in the Development of Protein-Downregulation-Based Antiandrogens.
Zhang R; Huang C; Xiao X; Zhou J
ChemMedChem; 2021 Jul; 16(13):2021-2033. PubMed ID: 33554455
[TBL] [Abstract][Full Text] [Related]
5. Targeting androgen receptor degradation with PROTACs from bench to bedside.
Jia X; Han X
Biomed Pharmacother; 2023 Feb; 158():114112. PubMed ID: 36508999
[TBL] [Abstract][Full Text] [Related]
6. PROTACs in the Management of Prostate Cancer.
Yedla P; Babalghith AO; Andra VV; Syed R
Molecules; 2023 Apr; 28(9):. PubMed ID: 37175108
[TBL] [Abstract][Full Text] [Related]
7. Non-Steroidal Androgen Receptor Antagonists and Prostate Cancer: A Survey on Chemical Structures Binding this Fast-Mutating Target.
Ferroni C; Varchi G
Curr Med Chem; 2019; 26(33):6053-6073. PubMed ID: 30209993
[TBL] [Abstract][Full Text] [Related]
8. Designed, synthesized and biological evaluation of proteolysis targeting chimeras (PROTACs) as AR degraders for prostate cancer treatment.
Liang JJ; Xie H; Yang RH; Wang N; Zheng ZJ; Zhou C; Wang YL; Wang ZJ; Liu HM; Shan LH; Ke Y
Bioorg Med Chem; 2021 Sep; 45():116331. PubMed ID: 34364224
[TBL] [Abstract][Full Text] [Related]
9. Modeling androgen receptor flexibility: a binding mode hypothesis of CYP17 inhibitors/antiandrogens for prostate cancer therapy.
Gianti E; Zauhar RJ
J Chem Inf Model; 2012 Oct; 52(10):2670-83. PubMed ID: 22924551
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological evaluation of niclosamide PROTACs.
Munoz E; Chen G; Hossain A; Wu S; Oceguera Nava E; Hang J; Lee T; Zhang Q; Wang G; Chen QH
Bioorg Med Chem Lett; 2022 Sep; 72():128870. PubMed ID: 35772635
[TBL] [Abstract][Full Text] [Related]
11. A critical update on the strategies towards modulators targeting androgen receptors.
Luan H; Xu P; Meng Y; Li Z; Bian J
Bioorg Med Chem; 2020 Jul; 28(13):115554. PubMed ID: 32546299
[TBL] [Abstract][Full Text] [Related]
12. Chemical Degradation of Androgen Receptor (AR) Using Bicalutamide Analog-Thalidomide PROTACs.
Kim GY; Song CW; Yang YS; Lee NR; Yoo HS; Son SH; Lee SJ; Park JS; Lee JK; Inn KS; Kim NJ
Molecules; 2021 Apr; 26(9):. PubMed ID: 33926033
[TBL] [Abstract][Full Text] [Related]
13. Antiandrogens in prostate cancer.
Reid P; Kantoff P; Oh W
Invest New Drugs; 1999; 17(3):271-84. PubMed ID: 10665479
[TBL] [Abstract][Full Text] [Related]
14. A narrative review of proteolytic targeting chimeras (PROTACs): future perspective for prostate cancer therapy.
Chen X; Shen H; Shao Y; Ma Q; Niu Y; Shang Z
Transl Androl Urol; 2021 Feb; 10(2):954-962. PubMed ID: 33718095
[TBL] [Abstract][Full Text] [Related]
15. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9
Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C
Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814
[TBL] [Abstract][Full Text] [Related]
16. Discovery of A031 as effective proteolysis targeting chimera (PROTAC) androgen receptor (AR) degrader for the treatment of prostate cancer.
Chen L; Han L; Mao S; Xu P; Xu X; Zhao R; Wu Z; Zhong K; Yu G; Wang X
Eur J Med Chem; 2021 Apr; 216():113307. PubMed ID: 33652354
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms and targeting of proteosome-dependent androgen receptor degradation in prostate cancer.
Fang Q; Cole RN; Wang Z
Am J Clin Exp Urol; 2022; 10(6):366-376. PubMed ID: 36636693
[TBL] [Abstract][Full Text] [Related]
18. Androgen receptor antagonists for prostate cancer therapy.
Helsen C; Van den Broeck T; Voet A; Prekovic S; Van Poppel H; Joniau S; Claessens F
Endocr Relat Cancer; 2014 Aug; 21(4):T105-18. PubMed ID: 24639562
[TBL] [Abstract][Full Text] [Related]
19. Ligand-independent androgen receptor activity is activation function-2-independent and resistant to antiandrogens in androgen refractory prostate cancer cells.
Dehm SM; Tindall DJ
J Biol Chem; 2006 Sep; 281(38):27882-93. PubMed ID: 16870607
[TBL] [Abstract][Full Text] [Related]
20. Advancements in Non-steroidal Antiandrogens as Potential Therapeutic Agents for the Treatment of Prostate Cancer.
Kaur P; Khatik GL
Mini Rev Med Chem; 2016; 16(7):531-46. PubMed ID: 26776222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]